Key facts
- Galderma reported H1 2026 net sales of $3.134 billion, a 24.6% increase year-on-year at constant currency.
- The company raised its full-year net sales growth forecast to 19-21% from 17-20%.
- Growth was broad-based across all product categories and geographies, including the U.S. and international markets.
- Core EBITDA reached $802 million, up 42.8% year-on-year at constant currency, with a margin of 25.6%.
- Core EPS grew 68.5% year-on-year to $2.34.
Swiss skincare firm Galderma reported record first-half 2026 net sales of $3.134 billion, representing a 24.6% increase year-on-year at constant currency. The company's performance was driven by broad-based, double-digit growth in both international markets and the U.S., as well as across all product categories.
Galderma's growth in Injectable Aesthetics was 12.1%, Dermatological Skincare was 16.4%, and Therapeutic Dermatology saw a significant 67.9% increase, with Nemluvio® contributing $433 million in net sales. The company also noted ongoing geographic expansion and innovation, including approvals for Relfydess™ in 33 international markets.
Core EBITDA for the first half reached $802 million, up 42.8% year-on-year at constant currency, with a margin of 25.6%, exceeding initial expectations. Core Earnings Per Share (EPS) grew 68.5% to $2.34, supported by strong EBITDA and reduced financing costs.
Based on this strong trajectory, Galderma has raised its full-year 2026 net sales growth guidance to 19-21% at constant currency, up from the previous 17-20% target. The company also confirmed its full-year Core EBITDA margin guidance of approximately 26% at constant currency. Galderma anticipates manageable exposure to U.S. tariffs and the ability to absorb potential consumer demand deterioration.